D.A. Davidson & Co. Ligand Pharmaceuticals Inc Transaction History

D.A. Davidson & Co.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$107.38 - $129.34 $330,086 - $397,591	-3,074 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$105.93 - $142.47 $149,255 - $200,740	1,409 Added 84.62%	3,074 $386,000
Q4 2018 Jan 29, 2019	SELL	$128.36 - $272.13 $91,135 - $193,212	-710 Reduced 29.89%	1,665 $226,000
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $60,397 - $78,504	-286 Reduced 10.75%	2,375 $652,000
Q2 2018 Aug 02, 2018	SELL	$150.77 - $207.98 $150 - $207	-1 Reduced 0.04%	2,661 $551,000
Q1 2018 May 04, 2018	BUY	$138.63 - $182.62 $2,079 - $2,739	15 Added 0.57%	2,662 $440,000
Q4 2017 Feb 08, 2018	SELL	$128.36 - $147.04 $10,653 - $12,204	-83 Reduced 3.04%	2,647 $362,000
Q3 2017 Nov 08, 2017	BUY	$120.91 - $137.94 $193,818 - $221,117	1,603 Added 142.24%	2,730 $371,000
Q2 2017 Aug 11, 2017	BUY	N/A	1,127	1,127 $0

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.07B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.